Ma Yu, Qiang Zhihui, Zhou Miaomiao, Zhang Tianyi, Li Zhuoyang, Zhong Haicheng, Chang Yue, Ning Zimeng, Liu Yun
Department of Respiratory and Critical Care Medicine, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
Front Med (Lausanne). 2024 Nov 21;11:1447716. doi: 10.3389/fmed.2024.1447716. eCollection 2024.
The aim of this study was to conduct a systematic review and meta-analysis of the incidence of inflammatory bowel disease-associated bronchiectasis (IBD-BE) and to explore the possible risk factors for IBD-BE, which could help to understand the pulmonary involvement in patients with IBD and to determine the global incidence of the disease.
We searched PubMed and EMBASE databases to identify information on the prevalence of IBD-BE among IBD patients in the published literature. Information was extracted on study design, country, year, IBD-BE testing method, IBD characteristics, number of IBD-BE cases and total number of IBD patients, and factors associated with IBD-BE. We conducted meta-analyses using random-effects or fixed-effects models to estimate the prevalence of IBD-BE among IBD patients.
Out of a total of 682 studies, we identified 16 studies that reported prevalence. These studies used a heterogeneous approach to identify IBD-BE. In these 16 studies, there were 92,191 patients with IBD, of whom 372 cases of IBD-BE were identified. The results of the meta-analysis showed that the overall prevalence of IBD-BE in IBD derived from the use of a random effects model was 5.0% (95% CI 2.0-12.0%). In contrast, the prevalence of IBD-BE in studies using high-resolution chest computed tomography (HRCT) imaging was 12% (95% CI 4-39%) using a random-effects model. When only retrospective studies with sample sizes greater than 100 ( = 6) were considered, the prevalence was 1% (95% CI 0-1%). However, when only retrospective studies with sample sizes less than 100 were included ( = 4), the prevalence was 29% (95% CI 6-100%); in prospective studies ( = 6), the combined prevalence was 11% (95% CI 4-29%). we performed a subgroup analysis of the differences in the incidence of IBD-BE between the different studies, each of which we subgrouped by type of study, type of disease, duration of disease, and diagnostic modality, and the results showed no significance. Future studies should standardize methods to identify IBD-BE cases and investigate the natural history and clinical course given the relatively high prevalence among IBD.
In this systematic review and meta-analysis, the prevalence of IBD-BE was 12% among studies with HRCT imaging, suggesting that bronchiectasis may be an underestimated common extraintestinal manifestation of IBD. Asymptomatic patients with IBD-BE may present with abnormalities on HRCT or pulmonary function tests. Future studies should standardize methods to identify IBD-BE cases and investigate the natural history and clinical course given the relatively high prevalence among IBD.
本研究旨在对炎症性肠病相关支气管扩张症(IBD-BE)的发病率进行系统评价和荟萃分析,并探讨IBD-BE可能的危险因素,这有助于了解IBD患者的肺部受累情况并确定该疾病的全球发病率。
我们检索了PubMed和EMBASE数据库,以确定已发表文献中IBD患者中IBD-BE患病率的信息。提取了关于研究设计、国家、年份、IBD-BE检测方法、IBD特征、IBD-BE病例数和IBD患者总数以及与IBD-BE相关因素的信息。我们使用随机效应或固定效应模型进行荟萃分析,以估计IBD患者中IBD-BE的患病率。
在总共682项研究中,我们确定了16项报告患病率的研究。这些研究采用了异质性方法来识别IBD-BE。在这16项研究中,有92191例IBD患者,其中372例被确定为IBD-BE。荟萃分析结果显示,使用随机效应模型得出的IBD患者中IBD-BE的总体患病率为5.0%(95%CI 2.0-12.0%)。相比之下,使用高分辨率胸部计算机断层扫描(HRCT)成像的研究中,使用随机效应模型得出的IBD-BE患病率为12%(95%CI 4-39%)。当仅考虑样本量大于100的回顾性研究(n=6)时,患病率为1%(95%CI 0-1%)。然而,当仅纳入样本量小于100的回顾性研究(n=4)时,患病率为29%(95%CI 6-100%);在前瞻性研究(n=6)中,合并患病率为11%(95%CI 4-29%)。我们对不同研究之间IBD-BE发病率的差异进行了亚组分析,根据研究类型、疾病类型、病程和诊断方式对每项研究进行亚组划分,结果显示无显著性差异。鉴于IBD中IBD-BE患病率相对较高,未来的研究应规范识别IBD-BE病例的方法,并调查其自然史和临床病程。
在这项系统评价和荟萃分析中,使用HRCT成像的研究中IBD-BE的患病率为12%,这表明支气管扩张症可能是IBD一种被低估的常见肠外表现。无症状的IBD-BE患者可能在HRCT或肺功能检查中出现异常。鉴于IBD中IBD-BE患病率相对较高,未来的研究应规范识别IBD-BE病例的方法,并调查其自然史和临床病程。